NOVEL LIPID 2ND MESSENGERS REGULATING BIOENERGETICS AND SIGNALING IN HUMAN MYOCARDIUM

调节人体心肌生物能量和信号传导的新型脂质第二信使

基本信息

  • 批准号:
    9281066
  • 负责人:
  • 金额:
    $ 38.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-07-01 至 2020-04-30
  • 项目状态:
    已结题

项目摘要

ABSTRACT Mitochondria are essential subcellular organelles that serve multiple functions in cellular biology including energy production, metabolism, lipid synthesis and signaling. Due to the ease of genetic manipulation in mouse models, a large majority of mechanistic inferences about heart failure have been made from gain of function or loss of function studies of specific enzymes during heart failure in mice. However, profound differences in the chemistry and physiology of murine mitochondria are present in comparison to human mitochondria. These include vast differences between murine and human mitochondrial phospholipid compositions, their repertoires of lipid 2nd messengers generated in response to stress, and the enzymic mediators responsible for modulating human mitochondrial signaling and bioenergetics. To bridge the translational gap between mouse and humans, we have focused our studies on the roles of lipid 2nd messengers present in human hearts and their impact on human heart mitochondrial bioenergetic and signaling functions. Recently, we have discovered a series of novel lipid 2nd messengers generated by human mitochondria which are dynamically regulated during the progression of heart failure in humans. Moreover, we have demonstrated that these novel lipid 2nd messengers modulate human mitochondrial energy production, bioenergetic efficiency and cellular signaling. Accordingly, a major goal of the proposed research is to identify the chemical mechanisms that integrate mitochondrial function with human cardiac myocyte physiology through novel lipid 2nd messengers we identified in human myocardium. Through utilization of an integrated series of mass spectrometric technologies we developed/employ including LC-MS/MS with charge-switch derivatization, multiple reaction monitoring, and high mass accuracy analysis of suites of product ions, we have identified and quantified many new natural products some of which we have already been shown to modulate human mitochondrial bioenergetics and signaling. The first goal is to identify the molecular mechanisms which initiate the generation of these novel lipid 2nd messengers from human myocardial phospholipids and identify the biochemical pathways which generate these natural products. The second goal of the proposed research is to identify the chemical diversity of these natural products and clarify their enantiomeric purity in extracts of human myocardium. Identification of enantiomerically pure natural products in human myocardium will demonstrate that they are produced by specific enzymes and that they are not products of adventitious oxidation. The third goal of the proposed studies is to mechanistically identify their roles in modulating human heart mitochondrial bioenergetics and signaling. Collectively, the proposed research is a unique opportunity to dramatically accelerate identification of the roles of human heart lipid 2nd messengers in precipitating human mitochondrial dysfunction that promotes the progression of human heart failure. This targeted translational approach will directly identify bona fide pharmacologic targets for treatment of human heart failure.
摘要 线粒体是重要的亚细胞器,在细胞生物学中发挥多种功能,包括 能量产生、代谢、脂质合成和信号传导。由于基因操作的容易性, 在小鼠模型中,大多数关于心力衰竭的机械推断是从获得 小鼠心力衰竭期间特定酶的功能或功能丧失研究。然而,深刻的 与人类相比,存在小鼠线粒体的化学和生理学差异 线粒体这些包括鼠和人的线粒体磷脂之间的巨大差异 组成,他们的剧目的脂质第二信使产生的压力,和酶, 负责调节人类线粒体信号传导和生物能量学的介质。弥合 由于小鼠和人类之间的翻译差距,我们将研究重点放在脂质2nd的作用上, 人类心脏中存在的信使及其对人类心脏线粒体生物能和 信号功能。近年来,我们发现了一系列新的脂质第二信使, 线粒体,其在人类心力衰竭的进展期间被动态调节。而且我们 已经证明这些新的脂质第二信使调节人线粒体能量产生, 生物能量效率和细胞信号传导。因此,拟议研究的一个主要目标是确定 整合线粒体功能与人类心肌细胞生理学的化学机制 通过我们在人类心肌中发现的新型脂质第二信使。通过利用综合 我们开发/采用的一系列质谱技术,包括LC-MS/MS电荷开关 衍生化、多反应监测和高质量准确度分析的产品离子套件,我们有 鉴定和量化了许多新的天然产物,其中一些我们已经被证明可以调节 人类线粒体生物能量学和信号传导。第一个目标是确定分子机制, 启动从人心肌磷脂产生这些新的脂质第二信使,并鉴定 产生这些天然产物的生化途径。拟议研究的第二个目标是 确定这些天然产物的化学多样性,并澄清其对映体纯度的提取物, 人体心肌人心肌组织中对映体纯天然产物的鉴定 证明它们是由特定的酶产生的,它们不是外源性的产物。 氧化所提出的研究的第三个目标是从机制上确定它们在调节人类免疫功能中的作用。 心脏线粒体生物能量学和信号传导。总的来说,拟议的研究是一个独特的机会, 大大加快了人类心脏脂质第二信使在人类心脏疾病中的作用的鉴定, 线粒体功能障碍,促进人类心力衰竭的进展。这种靶向翻译 该方法将直接识别用于治疗人类心力衰竭的真正药理学靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RICHARD W GROSS其他文献

RICHARD W GROSS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RICHARD W GROSS', 18)}}的其他基金

Novel Lipid 2nd Messengers Regulating Bioenergetics and Signaling in Human Myocardium
调节人体心肌生物能和信号传导的新型脂质第二信使
  • 批准号:
    10593961
  • 财政年份:
    2016
  • 资助金额:
    $ 38.13万
  • 项目类别:
Novel Lipid 2nd Messengers Regulating Bioenergetics and Signaling in Human Myocardium
调节人体心肌生物能和信号传导的新型脂质第二信使
  • 批准号:
    10378709
  • 财政年份:
    2016
  • 资助金额:
    $ 38.13万
  • 项目类别:
Novel Lipid 2nd Messengers Regulating Bioenergetics and Signaling in Human Myocardium
调节人体心肌生物能和信号传导的新型脂质第二信使
  • 批准号:
    10211266
  • 财政年份:
    2016
  • 资助金额:
    $ 38.13万
  • 项目类别:
THE INTEGRATED ROLES OF IPLA2G IN OBESITY, INFLAMMATION AND HEPATIC DYSFUNCTION
IPLA2G 在肥胖、炎症和肝功能障碍中的综合作用
  • 批准号:
    8817361
  • 财政年份:
    2014
  • 资助金额:
    $ 38.13万
  • 项目类别:
THE INTEGRATED ROLES OF IPLA2G IN OBESITY, INFLAMMATION AND HEPATIC DYSFUNCTION
IPLA2G 在肥胖、炎症和肝功能障碍中的综合作用
  • 批准号:
    9325506
  • 财政年份:
    2014
  • 资助金额:
    $ 38.13万
  • 项目类别:
Regulation of Myocardial Phospholipases and Lipases in Diabetic Myocardium
糖尿病心肌中心肌磷脂酶和脂肪酶的调节
  • 批准号:
    10551194
  • 财政年份:
    2013
  • 资助金额:
    $ 38.13万
  • 项目类别:
REGULATION OF MYOCARDIAL PHOSPHOLIPASES AND LIPASES IN DIABETIC MYOCARDIUM
糖尿病心肌中心肌磷脂酶和脂肪酶的调节
  • 批准号:
    8483030
  • 财政年份:
    2013
  • 资助金额:
    $ 38.13万
  • 项目类别:
REGULATION OF MYOCARDIAL PHOSPHOLIPASES AND LIPASES IN DIABETIC MYOCARDIUM
糖尿病心肌中心肌磷脂酶和脂肪酶的调节
  • 批准号:
    9309220
  • 财政年份:
    2013
  • 资助金额:
    $ 38.13万
  • 项目类别:
REGULATION OF MYOCARDIAL PHOSPHOLIPASES AND LIPASES IN DIABETIC MYOCARDIUM
糖尿病心肌中心肌磷脂酶和脂肪酶的调节
  • 批准号:
    9065644
  • 财政年份:
    2013
  • 资助金额:
    $ 38.13万
  • 项目类别:
Regulation of Myocardial Phospholipases and Lipases in Diabetic Myocardium
糖尿病心肌中心肌磷脂酶和脂肪酶的调节
  • 批准号:
    10367196
  • 财政年份:
    2013
  • 资助金额:
    $ 38.13万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 38.13万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 38.13万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 38.13万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 38.13万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 38.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 38.13万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 38.13万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 38.13万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 38.13万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 38.13万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了